
Adicet Bio, Inc. (ACET) Stock Ticker
ACET right now
Market factors today
Unlock the full ACET picture
About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
ACET stock facts
| Ticker symbol | ACET |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $84.3M |
| CEO | Chen Schor |
| Employees | 102 |
| Headquarters | Boston, MA, US |
| IPO date | 2018-01-26 |
| Website | www.adicetbio.com |
What you can see for ACET on Tickr
Live ACET price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ACET report.
Rankings
FAQ
What is the ticker symbol for Adicet Bio, Inc.?
The ticker symbol for Adicet Bio, Inc. is ACET, listed on the NASDAQ Global Market.
What is ACET?
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the…